Lisa Britt Sells 11,440 Shares of Thermo Fisher Scientific (NYSE:TMO) Stock

Key Points

• Insider sale: Thermo Fisher VP Lisa Britt sold 11,440 shares for approximately $7.01 million, reducing her direct position by 43.62% to 14,784 shares.
• Strong operating results: The company reported quarterly EPS of $6.03, exceeding estimates by $0.32, while revenue rose 10.5% year over year to $11.99 billion.
• Market outlook: Analysts maintain a “Moderate Buy” consensus with an average price target of $619.41; Thermo Fisher also declared a quarterly dividend of $0.47 per share.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) VP Lisa Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. This trade represents a 43.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $628.24 on Friday. The stock's fifty day moving average price is $539.33 and its 200-day moving average price is $508.86. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The firm has a market cap of $232.29 billion, a P/E ratio of 33.79, a P/E/G ratio of 2.50 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the firm earned $4.28 EPS. The firm's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on TMO shares. HSBC lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and reduced their price objective for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price objective on the stock. KeyCorp reaffirmed an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average price target of $619.41.

Institutional Trading of Thermo Fisher Scientific

Institutional investors and hedge funds have recently modified their holdings of the business. Banco de Sabadell S.A boosted its stake in Thermo Fisher Scientific by 1.1% during the 2nd quarter. Banco de Sabadell S.A now owns 4,684 shares of the medical research company's stock valued at $2,366,000 after purchasing an additional 53 shares in the last quarter. Chesapeake Wealth Management raised its holdings in Thermo Fisher Scientific by 0.6% during the 2nd quarter. Chesapeake Wealth Management now owns 3,725 shares of the medical research company's stock worth $1,868,000 after buying an additional 22 shares during the period. Keeler Thomas Management LLC boosted its stake in Thermo Fisher Scientific by 7.2% in the 2nd quarter. Keeler Thomas Management LLC now owns 1,911 shares of the medical research company's stock worth $958,000 after purchasing an additional 129 shares during the period. Legacy Financial Advisors Inc. grew its holdings in shares of Thermo Fisher Scientific by 5.9% during the second quarter. Legacy Financial Advisors Inc. now owns 2,097 shares of the medical research company's stock valued at $1,051,000 after buying an additional 117 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $708,000. 89.23% of the stock is owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.